Argos Therapeutics (ARGS) Receives News Sentiment Rating of 0.20

News articles about Argos Therapeutics (NASDAQ:ARGS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6507087658362 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Argos Therapeutics (ARGS) remained flat at $$0.16 during trading hours on Friday. 2,651,000 shares of the stock were exchanged, compared to its average volume of 3,280,000. Argos Therapeutics has a one year low of $0.13 and a one year high of $5.55. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46. The firm has a market cap of $14.32, a P/E ratio of -0.15 and a beta of 1.38.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2018/01/13/argos-therapeutics-args-earns-daily-media-impact-rating-of-0-20.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply